| . | Total . | Age Category . | |||
|---|---|---|---|---|---|
| 0–6 y . | 7–18 y . | 19–64 y . | 65–74 y . | ||
| No. of patients | 1 341 355 | 185 560 | 426 799 | 712 217 | 16 779 |
| Age, mean ± SD, y | 26.6 ± 18.6 | 4.4 ± 1.5 | 11.5 ± 3.2 | 40.5 ± 11.9 | 67.9 ± 2.7 |
| Male | 730 367 (54.5%) | 97 268 (52.4%) | 227 846 (53.4%) | 396 316 (55.7%) | 8937 (53.3%) |
| Underlying disease | |||||
| Asthma | 188 185 (14.0%) | 82 111 (44.3%) | 64 733 (15.2%) | 39 896 (5.6%) | 1445 (8.6%) |
| Chronic bronchitis/emphysema | 33 756 (2.5%) | 3337 (1.8%) | 7162 (1.7%) | 21 698 (3.1%) | 1559 (9.3%) |
| Cardiovascular disease | 87 470 (6.5%) | 5020 (2.7%) | 11 082 (2.6%) | 65 716 (9.2%) | 5652 (33.7%) |
| Cerebrovascular disease | 29 463 (2.2%) | 234 (0.13%) | 1023 (0.24%) | 25 114 (3.5%) | 3092 (18.4%) |
| Neurological disease | 141 511 (10.6%) | 2846 (1.5%) | 18 162 (4.3%) | 115 756 (16.3%) | 4747 (28.3%) |
| Liver disease | 24 265 (1.8%) | 357 (0.19%) | 1250 (0.29%) | 21 376 (3.0%) | 1282 (7.6%) |
| Renal disease | 24 880 (1.9%) | 2852 (1.5%) | 7123 (1.7%) | 13 969 (2.0%) | 936 (5.6%) |
| Diabetes mellitus | 65 384 (4.9%) | 161 (0.09%) | 1770 (0.41%) | 58 085 (8.2%) | 5368 (32.0%) |
| Malignant tumor | 20 927 (1.6%) | 216 (0.12%) | 902 (0.21%) | 17 665 (2.5%) | 2144 (12.8%) |
| Collagen vascular disease | 22 079 (1.7%) | 2953 (1.6%) | 4991 (1.2%) | 13 305 (1.9%) | 830 (5.0%) |
| Immunosuppression | 16 063 (1.2%) | 1268 (0.68%) | 2951 (0.69%) | 11 199 (1.6%) | 645 (3.8%) |
| Inpatient at influenza diagnosis | 1477 (0.11%) | 567 (0.31%) | 268 (0.06%) | 545 (0.08%) | 97 (0.58%) |
| No. of influenza occurrences per season | |||||
| 1 | 1 312 005 (97.8%) | 176 014 (94.9%) | 413 726 (96.9%) | 705 589 (99.1%) | 16 676 (99.4%) |
| 2 | 28 914 (2.2%) | 9326 (5.0%) | 12 910 (3.0%) | 6577 (0.92%) | 101 (0.60%) |
| ≥3 | 436 (0.03%) | 220 (0.12%) | 163 (0.04%) | 51 (0.01%) | 2 (0.01%) |
| Types of influenza virus | |||||
| A | 622 679 (46.4%) | 85 450 (46.1%) | 171 212 (40.1%) | 358 012 (50.3%) | 8005 (47.7%) |
| B | 293 378 (21.9%) | 41 382 (22.3%) | 118 944 (27.9%) | 129 526 (18.2%) | 3526 (21.0%) |
| Unknown | 425 298 (31.7%) | 58 728 (31.7%) | 136 643 (32.0%) | 224 679 (31.6%) | 5248 (31.3%) |
| Anti-influenza drug | |||||
| Baloxavir | 276 595 (20.6%) | 12 429 (6.7%) | 82 217 (19.3%) | 178 094 (25.0%) | 3855 (23.0%) |
| Oseltamivir | 369 583 (27.6%) | 139 252 (75.0%) | 59 624 (14.0%) | 165 742 (23.3%) | 4965 (29.6%) |
| Laninamivir | 476 355 (35.5%) | 12 571 (6.8%) | 180 809 (42.4%) | 277 154 (38.9%) | 5821 (34.7%) |
| Zanamivir | 122 851 (9.2%) | 5825 (3.1%) | 80 537 (18.9%) | 35 907 (5.0%) | 582 (3.5%) |
| Peramivir | 21 777 (1.6%) | 1532 (0.83%) | 3955 (0.93%) | 15 627 (2.2%) | 663 (4.0%) |
| No prescription | 74 194 (5.5%) | 13 951 (7.5%) | 19 657 (4.6%) | 39 693 (5.6%) | 893 (5.3%) |
| . | Total . | Age Category . | |||
|---|---|---|---|---|---|
| 0–6 y . | 7–18 y . | 19–64 y . | 65–74 y . | ||
| No. of patients | 1 341 355 | 185 560 | 426 799 | 712 217 | 16 779 |
| Age, mean ± SD, y | 26.6 ± 18.6 | 4.4 ± 1.5 | 11.5 ± 3.2 | 40.5 ± 11.9 | 67.9 ± 2.7 |
| Male | 730 367 (54.5%) | 97 268 (52.4%) | 227 846 (53.4%) | 396 316 (55.7%) | 8937 (53.3%) |
| Underlying disease | |||||
| Asthma | 188 185 (14.0%) | 82 111 (44.3%) | 64 733 (15.2%) | 39 896 (5.6%) | 1445 (8.6%) |
| Chronic bronchitis/emphysema | 33 756 (2.5%) | 3337 (1.8%) | 7162 (1.7%) | 21 698 (3.1%) | 1559 (9.3%) |
| Cardiovascular disease | 87 470 (6.5%) | 5020 (2.7%) | 11 082 (2.6%) | 65 716 (9.2%) | 5652 (33.7%) |
| Cerebrovascular disease | 29 463 (2.2%) | 234 (0.13%) | 1023 (0.24%) | 25 114 (3.5%) | 3092 (18.4%) |
| Neurological disease | 141 511 (10.6%) | 2846 (1.5%) | 18 162 (4.3%) | 115 756 (16.3%) | 4747 (28.3%) |
| Liver disease | 24 265 (1.8%) | 357 (0.19%) | 1250 (0.29%) | 21 376 (3.0%) | 1282 (7.6%) |
| Renal disease | 24 880 (1.9%) | 2852 (1.5%) | 7123 (1.7%) | 13 969 (2.0%) | 936 (5.6%) |
| Diabetes mellitus | 65 384 (4.9%) | 161 (0.09%) | 1770 (0.41%) | 58 085 (8.2%) | 5368 (32.0%) |
| Malignant tumor | 20 927 (1.6%) | 216 (0.12%) | 902 (0.21%) | 17 665 (2.5%) | 2144 (12.8%) |
| Collagen vascular disease | 22 079 (1.7%) | 2953 (1.6%) | 4991 (1.2%) | 13 305 (1.9%) | 830 (5.0%) |
| Immunosuppression | 16 063 (1.2%) | 1268 (0.68%) | 2951 (0.69%) | 11 199 (1.6%) | 645 (3.8%) |
| Inpatient at influenza diagnosis | 1477 (0.11%) | 567 (0.31%) | 268 (0.06%) | 545 (0.08%) | 97 (0.58%) |
| No. of influenza occurrences per season | |||||
| 1 | 1 312 005 (97.8%) | 176 014 (94.9%) | 413 726 (96.9%) | 705 589 (99.1%) | 16 676 (99.4%) |
| 2 | 28 914 (2.2%) | 9326 (5.0%) | 12 910 (3.0%) | 6577 (0.92%) | 101 (0.60%) |
| ≥3 | 436 (0.03%) | 220 (0.12%) | 163 (0.04%) | 51 (0.01%) | 2 (0.01%) |
| Types of influenza virus | |||||
| A | 622 679 (46.4%) | 85 450 (46.1%) | 171 212 (40.1%) | 358 012 (50.3%) | 8005 (47.7%) |
| B | 293 378 (21.9%) | 41 382 (22.3%) | 118 944 (27.9%) | 129 526 (18.2%) | 3526 (21.0%) |
| Unknown | 425 298 (31.7%) | 58 728 (31.7%) | 136 643 (32.0%) | 224 679 (31.6%) | 5248 (31.3%) |
| Anti-influenza drug | |||||
| Baloxavir | 276 595 (20.6%) | 12 429 (6.7%) | 82 217 (19.3%) | 178 094 (25.0%) | 3855 (23.0%) |
| Oseltamivir | 369 583 (27.6%) | 139 252 (75.0%) | 59 624 (14.0%) | 165 742 (23.3%) | 4965 (29.6%) |
| Laninamivir | 476 355 (35.5%) | 12 571 (6.8%) | 180 809 (42.4%) | 277 154 (38.9%) | 5821 (34.7%) |
| Zanamivir | 122 851 (9.2%) | 5825 (3.1%) | 80 537 (18.9%) | 35 907 (5.0%) | 582 (3.5%) |
| Peramivir | 21 777 (1.6%) | 1532 (0.83%) | 3955 (0.93%) | 15 627 (2.2%) | 663 (4.0%) |
| No prescription | 74 194 (5.5%) | 13 951 (7.5%) | 19 657 (4.6%) | 39 693 (5.6%) | 893 (5.3%) |
| . | Total . | Age Category . | |||
|---|---|---|---|---|---|
| 0–6 y . | 7–18 y . | 19–64 y . | 65–74 y . | ||
| No. of patients | 1 341 355 | 185 560 | 426 799 | 712 217 | 16 779 |
| Age, mean ± SD, y | 26.6 ± 18.6 | 4.4 ± 1.5 | 11.5 ± 3.2 | 40.5 ± 11.9 | 67.9 ± 2.7 |
| Male | 730 367 (54.5%) | 97 268 (52.4%) | 227 846 (53.4%) | 396 316 (55.7%) | 8937 (53.3%) |
| Underlying disease | |||||
| Asthma | 188 185 (14.0%) | 82 111 (44.3%) | 64 733 (15.2%) | 39 896 (5.6%) | 1445 (8.6%) |
| Chronic bronchitis/emphysema | 33 756 (2.5%) | 3337 (1.8%) | 7162 (1.7%) | 21 698 (3.1%) | 1559 (9.3%) |
| Cardiovascular disease | 87 470 (6.5%) | 5020 (2.7%) | 11 082 (2.6%) | 65 716 (9.2%) | 5652 (33.7%) |
| Cerebrovascular disease | 29 463 (2.2%) | 234 (0.13%) | 1023 (0.24%) | 25 114 (3.5%) | 3092 (18.4%) |
| Neurological disease | 141 511 (10.6%) | 2846 (1.5%) | 18 162 (4.3%) | 115 756 (16.3%) | 4747 (28.3%) |
| Liver disease | 24 265 (1.8%) | 357 (0.19%) | 1250 (0.29%) | 21 376 (3.0%) | 1282 (7.6%) |
| Renal disease | 24 880 (1.9%) | 2852 (1.5%) | 7123 (1.7%) | 13 969 (2.0%) | 936 (5.6%) |
| Diabetes mellitus | 65 384 (4.9%) | 161 (0.09%) | 1770 (0.41%) | 58 085 (8.2%) | 5368 (32.0%) |
| Malignant tumor | 20 927 (1.6%) | 216 (0.12%) | 902 (0.21%) | 17 665 (2.5%) | 2144 (12.8%) |
| Collagen vascular disease | 22 079 (1.7%) | 2953 (1.6%) | 4991 (1.2%) | 13 305 (1.9%) | 830 (5.0%) |
| Immunosuppression | 16 063 (1.2%) | 1268 (0.68%) | 2951 (0.69%) | 11 199 (1.6%) | 645 (3.8%) |
| Inpatient at influenza diagnosis | 1477 (0.11%) | 567 (0.31%) | 268 (0.06%) | 545 (0.08%) | 97 (0.58%) |
| No. of influenza occurrences per season | |||||
| 1 | 1 312 005 (97.8%) | 176 014 (94.9%) | 413 726 (96.9%) | 705 589 (99.1%) | 16 676 (99.4%) |
| 2 | 28 914 (2.2%) | 9326 (5.0%) | 12 910 (3.0%) | 6577 (0.92%) | 101 (0.60%) |
| ≥3 | 436 (0.03%) | 220 (0.12%) | 163 (0.04%) | 51 (0.01%) | 2 (0.01%) |
| Types of influenza virus | |||||
| A | 622 679 (46.4%) | 85 450 (46.1%) | 171 212 (40.1%) | 358 012 (50.3%) | 8005 (47.7%) |
| B | 293 378 (21.9%) | 41 382 (22.3%) | 118 944 (27.9%) | 129 526 (18.2%) | 3526 (21.0%) |
| Unknown | 425 298 (31.7%) | 58 728 (31.7%) | 136 643 (32.0%) | 224 679 (31.6%) | 5248 (31.3%) |
| Anti-influenza drug | |||||
| Baloxavir | 276 595 (20.6%) | 12 429 (6.7%) | 82 217 (19.3%) | 178 094 (25.0%) | 3855 (23.0%) |
| Oseltamivir | 369 583 (27.6%) | 139 252 (75.0%) | 59 624 (14.0%) | 165 742 (23.3%) | 4965 (29.6%) |
| Laninamivir | 476 355 (35.5%) | 12 571 (6.8%) | 180 809 (42.4%) | 277 154 (38.9%) | 5821 (34.7%) |
| Zanamivir | 122 851 (9.2%) | 5825 (3.1%) | 80 537 (18.9%) | 35 907 (5.0%) | 582 (3.5%) |
| Peramivir | 21 777 (1.6%) | 1532 (0.83%) | 3955 (0.93%) | 15 627 (2.2%) | 663 (4.0%) |
| No prescription | 74 194 (5.5%) | 13 951 (7.5%) | 19 657 (4.6%) | 39 693 (5.6%) | 893 (5.3%) |
| . | Total . | Age Category . | |||
|---|---|---|---|---|---|
| 0–6 y . | 7–18 y . | 19–64 y . | 65–74 y . | ||
| No. of patients | 1 341 355 | 185 560 | 426 799 | 712 217 | 16 779 |
| Age, mean ± SD, y | 26.6 ± 18.6 | 4.4 ± 1.5 | 11.5 ± 3.2 | 40.5 ± 11.9 | 67.9 ± 2.7 |
| Male | 730 367 (54.5%) | 97 268 (52.4%) | 227 846 (53.4%) | 396 316 (55.7%) | 8937 (53.3%) |
| Underlying disease | |||||
| Asthma | 188 185 (14.0%) | 82 111 (44.3%) | 64 733 (15.2%) | 39 896 (5.6%) | 1445 (8.6%) |
| Chronic bronchitis/emphysema | 33 756 (2.5%) | 3337 (1.8%) | 7162 (1.7%) | 21 698 (3.1%) | 1559 (9.3%) |
| Cardiovascular disease | 87 470 (6.5%) | 5020 (2.7%) | 11 082 (2.6%) | 65 716 (9.2%) | 5652 (33.7%) |
| Cerebrovascular disease | 29 463 (2.2%) | 234 (0.13%) | 1023 (0.24%) | 25 114 (3.5%) | 3092 (18.4%) |
| Neurological disease | 141 511 (10.6%) | 2846 (1.5%) | 18 162 (4.3%) | 115 756 (16.3%) | 4747 (28.3%) |
| Liver disease | 24 265 (1.8%) | 357 (0.19%) | 1250 (0.29%) | 21 376 (3.0%) | 1282 (7.6%) |
| Renal disease | 24 880 (1.9%) | 2852 (1.5%) | 7123 (1.7%) | 13 969 (2.0%) | 936 (5.6%) |
| Diabetes mellitus | 65 384 (4.9%) | 161 (0.09%) | 1770 (0.41%) | 58 085 (8.2%) | 5368 (32.0%) |
| Malignant tumor | 20 927 (1.6%) | 216 (0.12%) | 902 (0.21%) | 17 665 (2.5%) | 2144 (12.8%) |
| Collagen vascular disease | 22 079 (1.7%) | 2953 (1.6%) | 4991 (1.2%) | 13 305 (1.9%) | 830 (5.0%) |
| Immunosuppression | 16 063 (1.2%) | 1268 (0.68%) | 2951 (0.69%) | 11 199 (1.6%) | 645 (3.8%) |
| Inpatient at influenza diagnosis | 1477 (0.11%) | 567 (0.31%) | 268 (0.06%) | 545 (0.08%) | 97 (0.58%) |
| No. of influenza occurrences per season | |||||
| 1 | 1 312 005 (97.8%) | 176 014 (94.9%) | 413 726 (96.9%) | 705 589 (99.1%) | 16 676 (99.4%) |
| 2 | 28 914 (2.2%) | 9326 (5.0%) | 12 910 (3.0%) | 6577 (0.92%) | 101 (0.60%) |
| ≥3 | 436 (0.03%) | 220 (0.12%) | 163 (0.04%) | 51 (0.01%) | 2 (0.01%) |
| Types of influenza virus | |||||
| A | 622 679 (46.4%) | 85 450 (46.1%) | 171 212 (40.1%) | 358 012 (50.3%) | 8005 (47.7%) |
| B | 293 378 (21.9%) | 41 382 (22.3%) | 118 944 (27.9%) | 129 526 (18.2%) | 3526 (21.0%) |
| Unknown | 425 298 (31.7%) | 58 728 (31.7%) | 136 643 (32.0%) | 224 679 (31.6%) | 5248 (31.3%) |
| Anti-influenza drug | |||||
| Baloxavir | 276 595 (20.6%) | 12 429 (6.7%) | 82 217 (19.3%) | 178 094 (25.0%) | 3855 (23.0%) |
| Oseltamivir | 369 583 (27.6%) | 139 252 (75.0%) | 59 624 (14.0%) | 165 742 (23.3%) | 4965 (29.6%) |
| Laninamivir | 476 355 (35.5%) | 12 571 (6.8%) | 180 809 (42.4%) | 277 154 (38.9%) | 5821 (34.7%) |
| Zanamivir | 122 851 (9.2%) | 5825 (3.1%) | 80 537 (18.9%) | 35 907 (5.0%) | 582 (3.5%) |
| Peramivir | 21 777 (1.6%) | 1532 (0.83%) | 3955 (0.93%) | 15 627 (2.2%) | 663 (4.0%) |
| No prescription | 74 194 (5.5%) | 13 951 (7.5%) | 19 657 (4.6%) | 39 693 (5.6%) | 893 (5.3%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
